Affinage

ARID2

AT-rich interactive domain-containing protein 2 · UniProt Q68CP9

Length
1835 aa
Mass
197.4 kDa
Annotated
2026-06-09
62 papers in source corpus 21 papers cited in narrative 22 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 8/8 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

ARID2 (BAF200) is a defining, gene-selectivity subunit of the PBAF SWI/SNF chromatin-remodeling complex that directs context-specific transcriptional programs in development, immunity, DNA repair, and tumor suppression (PMID:15985610). As a PBAF specificity factor it is required for activation of interferon-responsive genes and assembles into more than one PBAF configuration, including a canonical BRG1-containing form and a distinct BRG1-independent, BAF180-containing form (PMID:15985610, PMID:28381560). Its ARID domain has the structural potential for high-affinity DNA binding (PMID:30535613). Beyond transcriptional activation, ARID2 acts as a transcriptional repressor of oncogenic and metastasis-promoting targets: it interacts with E2F1 to reduce E2F1/RNA Pol II occupancy of CCND1 and CCNE1 and slow G1/S progression (PMID:27351279), recruits DNMT1 to methylate and silence the Snail promoter to suppress EMT and metastasis (PMID:32071245), and represses CD44 and (in cooperation with PBAF/PRC2 chromatin) restrains additional gene programs (PMID:27095763). ARID2 supports genome integrity through two repair pathways, enabling XPG accumulation for nucleotide excision repair and recruiting Rad51 to double-strand breaks for homologous recombination, and it co-maintains enhancer-promoter loops for BRCA1, RAD51, and 53BP1 (PMID:28238438, PMID:28381560, PMID:35017665). In vivo, ARID2 is required for cardiac morphogenesis and coronary artery development, fetal HSC expansion and erythropoiesis, lymphoid lineage commitment, and B cell differentiation (PMID:25299188, PMID:29482581, PMID:33346030, PMID:41256460). ARID2 protein levels are regulated by the ubiquitin system: it is a pomalidomide-induced CRL4CRBN neosubstrate whose degradation requires the PBAF subunit BRD7, and it is stabilized by the deubiquitinase USP2 (PMID:32958952, PMID:36567903). ARID2 haploinsufficiency is associated with enhanced RAS-MAPK (ERK1/2) signaling through reduced IFITM1, with patient iPSCs showing impaired neuronal differentiation (PMID:33051312).

Mechanistic history

Synthesis pass · year-by-year structured walk · 16 steps
  1. 2005 High

    Established ARID2 as a dedicated PBAF specificity subunit, answering whether PBAF and BAF complexes regulate distinct genes and which subunit confers that selectivity.

    Evidence Biochemical complex purification and in vivo transcription assays on interferon-responsive promoters

    PMID:15985610

    Open questions at the time
    • Did not define which DNA sequences or cofactors ARID2 recognizes to confer specificity
    • Generality beyond interferon-responsive genes untested
  2. 2014 High

    Demonstrated an essential developmental requirement for ARID2 in heart and coronary vessel formation, moving it from a transcriptional factor to a physiological morphogenesis regulator.

    Evidence Conditional knockout mouse with embryonic histology and phenotyping

    PMID:25299188

    Open questions at the time
    • Target genes driving the cardiac phenotype not defined
    • Mechanism of subepicardial-to-arterial cell fate transition unresolved
  3. 2016 Medium

    Defined a direct transcriptional-repressor mechanism for tumor suppression by linking ARID2 to E2F1-driven cell-cycle gene control and to CD44 repression.

    Evidence Co-IP, ChIP of E2F1/Pol II at CCND1/CCNE1, luciferase reporter, xenografts in HCC models

    PMID:27095763 PMID:27351279

    Open questions at the time
    • Whether repression requires intact PBAF remodeling activity not tested
    • Direct ARID2 promoter occupancy versus indirect effects not fully separated
  4. 2017 High

    Showed ARID2 is required for two distinct DNA repair pathways, explaining how its loss promotes mutagenesis and tumorigenesis.

    Evidence CRISPR KO with XPG recruitment assays (NER) and reciprocal Co-IP plus HR/Rad51 recruitment assays; identification of two PBAF subforms

    PMID:28238438 PMID:28381560

    Open questions at the time
    • Structural basis of ARID2-Rad51 and ARID2-XPG recruitment not resolved
    • Relative contribution of NER versus HR to tumor phenotypes unclear
  5. 2017 Medium

    Identified upstream transcriptional control of ARID2 itself, with HBV HBx repressing ARID2 via ATOH1 elements to promote HCC.

    Evidence Promoter deletion/luciferase, ATOH1 site mutagenesis, ectopic expression and migration assays

    PMID:28498550

    Open questions at the time
    • Endogenous role of ATOH1 in normal ARID2 regulation untested
    • Single-lab promoter-level evidence
  6. 2018 Low

    Provided the structural starting point for understanding ARID2-DNA recognition by assigning the ARID domain backbone.

    Evidence NMR backbone chemical shift assignment of the human BAF200 ARID domain

    PMID:30535613

    Open questions at the time
    • No functional mutagenesis validating DNA binding
    • DNA binding specificity within PBAF context not established
  7. 2018 High

    Extended ARID2's essential roles to the hematopoietic system, establishing a tumor-suppressor function in leukemia and a requirement for HSC expansion and erythropoiesis.

    Evidence Multiple Cre conditional knockouts, fetal liver/BM transplantation, RNA-seq, MLL-AF9 leukemia model

    PMID:29482581

    Open questions at the time
    • Direct transcriptional targets in HSCs not pinpointed
    • Mechanism distinguishing erythroid versus stem-cell defects unclear
  8. 2020 High

    Resolved the metastasis-suppressor mechanism in HCC by tying ARID2 to DNMT1-mediated Snail promoter silencing and mapping it to the C2H2 domain.

    Evidence KO mouse HCC models, ChIP of DNMT1, bisulfite sequencing, domain mutants, metastasis assays

    PMID:32071245

    Open questions at the time
    • How ARID2 physically recruits DNMT1 not structurally defined
    • Whether this mechanism operates outside HCC untested
  9. 2020 High

    Defined ARID2 protein-level regulation by the ubiquitin-proteasome system, identifying it as a pomalidomide-induced CRL4CRBN neosubstrate dependent on BRD7.

    Evidence Proteomics, Co-IP, BRD7 knockdown, pomalidomide degradation and MYC expression assays in myeloma

    PMID:32958952

    Open questions at the time
    • Degron determinants on ARID2 not mapped
    • Physiological (non-drug) triggers of CRL4CRBN-mediated ARID2 turnover unknown
  10. 2020 Medium

    Connected ARID2 loss to anti-tumor immunity and to RAS-MAPK signaling, linking its chromatin function to STAT1/chemokine programs and IFITM1-CAV1 control of ERK.

    Evidence Melanoma KO with anti-PD-L1 treatment and CD8 infiltration; shRNA/KO with ERK phosphorylation, patient iPSC differentiation and haploinsufficient mice; lymphoid-lineage conditional KO with RNA-seq

    PMID:33051312 PMID:33333124 PMID:33346030

    Open questions at the time
    • Direct chromatin targets bridging ARID2 to STAT1/IFITM1 not defined
    • Whether immune and MAPK effects share a common transcriptional node unclear
  11. 2021 High

    Identified a context-dependent driver downstream of ARID2 loss in lung adenocarcinoma, defining HSPA1A as a selective vulnerability.

    Evidence Kras GEMMs, integrated ChIP-seq/RNA-seq, HSPA1A knockdown and inhibitor in cells and animals

    PMID:34858604

    Open questions at the time
    • Why HSPA1A dependency is ARID2-specific not mechanistically resolved
    • Direct ARID2 occupancy at HSPA1A regulatory regions not detailed
  12. 2022 High

    Uncovered a metabolic and signaling role by which ARID2 represses JAK2-STAT5-PPARgamma to limit hepatic steatosis through CARM1/NEDD4L-dependent JAK2 degradation.

    Evidence Liver-specific KO with HFD, ChIP of CARM1/H3R17me2a at NEDD4L, ubiquitination assays, JAK2 inhibitor rescue, clinical samples

    PMID:36396719

    Open questions at the time
    • How ARID2 selects the NEDD4L locus for CARM1 recruitment unresolved
    • Relevance to non-hepatic tissues untested
  13. 2022 Medium

    Revealed a therapeutic synthetic-lethal interaction, showing ARID2 and BRD4 jointly sustain DSB-repair gene enhancer loops.

    Evidence Drug screen with JQ1 in ARID2-depleted HCC, DSB and HR/NHEJ assays, chromatin conformation capture, BRCA1/RAD51/53BP1 expression

    PMID:35017665

    Open questions at the time
    • Direct cooperative binding of ARID2 and BRD4 at the loops not shown
    • Single-lab evidence
  14. 2022 Medium

    Identified USP2 as a deubiquitinase that stabilizes ARID2, complementing the CRL4CRBN degradation axis.

    Evidence IP-MS, Co-IP, immunofluorescence colocalization, CHX chase, ubiquitination and migration assays

    PMID:36567903

    Open questions at the time
    • DUB cleavage site / ubiquitin linkage on ARID2 not mapped
    • Single-lab, reciprocal in vivo validation limited
  15. 2024 Medium

    Linked PBAF/ARID2 to repressive chromatin and REST function, and extended ARID2 tumor-suppressor logic to TFE3-RCC via ERBB3.

    Evidence ChIP-seq of SWI/SNF and REST occupancy in melanoma (preprint); ARID2 KO with PRCC-TFE3/ERBB3 ChIP and ERBB3 inhibitor sensitivity in TFE3-RCC

    PMID:39727945

    Open questions at the time
    • Mechanism of PBAF-PRC2 co-occupancy at repressive regions not fully defined
    • Melanoma REST findings remain in preprint
  16. 2025 Medium

    Established a requirement for ARID2 in B cell differentiation and humoral immunity, refining its hematopoietic role to lineage-specific gene programs.

    Evidence Conditional KO (Mb1-Cre, CD19-Cre), flow cytometry, stage-specific RNA-seq, immunization and germinal center assays (preprint)

    PMID:41256460

    Open questions at the time
    • Direct ARID2 targets controlling BCR-signaling genes not identified
    • Findings remain in preprint pending peer review

Open questions

Synthesis pass · forward-looking unresolved questions
  • How ARID2 selects its genomic binding sites and recruits distinct effectors (DNMT1, CARM1, Rad51, XPG, E2F1) at different loci remains unresolved at the structural and biochemical level.
  • No DNA-binding specificity defined for the ARID/C2H2 domains in PBAF context
  • No structure of ARID2 within an assembled PBAF complex
  • Rules governing activator-versus-repressor outcomes unknown

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0060090 molecular adaptor activity 4 GO:0140110 transcription regulator activity 4 GO:0003677 DNA binding 1
Localization
GO:0000228 nuclear chromosome 3 GO:0005634 nucleus 3
Pathway
R-HSA-1266738 Developmental Biology 4 R-HSA-74160 Gene expression (Transcription) 4 R-HSA-168256 Immune System 3 R-HSA-392499 Metabolism of proteins 3 R-HSA-4839726 Chromatin organization 3 R-HSA-73894 DNA Repair 3 R-HSA-1640170 Cell Cycle 1
Partners
BRD4BRD7CARM1DNMT1E2F1RAD51USP2
Complex memberships
PBAF SWI/SNF complex

Evidence

Reading pass · 22 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2005 ARID2 (BAF200) is a specificity subunit of the PBAF chromatin-remodeling complex (SWI/SNF family) required for selective transcriptional activation of interferon-responsive genes; PBAF and BAF regulate expression of distinct gene sets, and this selectivity requires BAF200 but not the previously described PBAF-specificity subunit BAF180. Biochemical complex purification, in vivo gene expression studies comparing PBAF vs BAF complex activity on interferon-responsive gene promoters Genes & development High 15985610
2014 BAF200 (ARID2) is required for heart morphogenesis and coronary artery development in vivo; BAF200 mutant mice are embryonic lethal with thin myocardium, ventricular septum defect, common atrioventricular valve, double outlet right ventricle, and reduced intramyocardial coronary arteries, indicating a role in migration and differentiation of subepicardial venous cells into arterial endothelial cells. BAF200 mutant mouse generation (conditional knockout), histology, embryonic phenotype analysis PloS one High 25299188
2016 ARID2 suppresses hepatoma cell proliferation and tumor growth by physically interacting with E2F1 and decreasing E2F1/RNA Pol II binding to the promoters of CCND1 (cyclin D1) and CCNE1 (cyclin E1), thereby repressing their transcription and retarding G1/S cell cycle progression. Co-immunoprecipitation (physical interaction with E2F1), ChIP assay (E2F1/RNA Pol II binding to CCND1/CCNE1 promoters), gain/loss-of-function proliferation assays, mouse xenograft tumor growth Oncotarget Medium 27351279
2017 ARID2 is required for nucleotide excision repair (NER): ARID2 knockout in HCC cells attenuates NER at UV-induced and chemically induced DNA damage sites because XPG (xeroderma pigmentosum group G protein) cannot accumulate without ARID2, resulting in susceptibility to carcinogens and increased somatic mutation burden. CRISPR/Cas9 ARID2 knockout, gene expression profiling, UV irradiation sensitivity assays, XPG recruitment assay, large-scale public dataset validation Journal of hepatology High 28238438
2017 Baf200 (ARID2) facilitates homologous recombination-dependent DNA double-strand break (DSB) repair by recruiting Rad51 to DSBs; Baf200 and Rad51 are present in the same complex mediated by C-terminal sequences in both proteins. Baf200 also forms at least two distinct PBAF complexes: one canonical form containing BRG1, and another containing Baf180 but not BRG1. Cytological and biochemical approaches (co-immunoprecipitation, homology-directed repair assays, Rad51 recruitment assays, cell survival after DNA damage) The Journal of biological chemistry High 28381560
2018 Baf200 (ARID2) is required for fetal hematopoietic stem cell (HSC) expansion and erythropoiesis; Tie2-Cre-mediated loss causes perinatal death from defective erythropoiesis; conditional knockout HSCs show impaired long-term reconstitution potential in transplantation assays; loss of Baf200 in MLL-AF9-driven leukemia accelerates tumor burden, indicating a tumor suppressor role in hematopoiesis. Tie2-Cre, Vav-iCre, Mx1-Cre conditional knockouts, fetal liver/bone marrow transplantation, RNA-seq, cell cycle/apoptosis assays, MLL-AF9 leukemia mouse model Journal of hematology & oncology High 29482581
2019 HBV core protein (HBc) physically interacts with BAF200 (ARID2) C-terminus, disrupting PBAF complex stability; this interaction suppresses IFITM1 transcription, where basal IFITM1 expression depends on BAF200 rather than the JAK-STAT1 pathway. HBc-mediated PBAF disruption thus inhibits IFNα-induced IFITM1 expression, contributing to HBV immune evasion. Yeast two-hybrid (initial identification), co-immunoprecipitation in 293T, HepG2, HepG2-NTCP cells, IFITM1 luciferase/expression assays, HBV replication assays Viruses Medium 31075894
2020 ARID2 suppresses HCC metastasis and epithelial-mesenchymal transition (EMT) by recruiting DNMT1 to the Snail promoter, increasing promoter methylation and inhibiting Snail transcription. ARID2 mutants with disrupted C2H2 domain lose this metastasis suppressor function. ARID2 KO in HCC mouse models, in vitro migration/invasion assays, in vivo metastasis assays, ChIP assay (DNMT1 recruitment to Snail promoter), bisulfite sequencing (promoter methylation), domain mutant functional analysis Proceedings of the National Academy of Sciences of the United States of America High 32071245
2020 ARID2 is a pomalidomide-induced neosubstrate of the CRL4CRBN E3 ubiquitin ligase complex; pomalidomide induces ARID2 degradation in multiple myeloma cells, and BRD7 (another PBAF subunit) is critical for this pomalidomide-induced ARID2 degradation. ARID2 regulates transcription of pomalidomide target genes including MYC. Proteomics, co-immunoprecipitation, BRD7 knockdown, pomalidomide treatment with protein degradation assays, MYC expression assays, proliferation assays Nature chemical biology High 32958952
2020 ARID2 deficiency leads to STAT1 upregulation, which subsequently causes increased expression of T-cell-attracting chemokines CXCL9, CXCL10, and CCL5, sensitizing melanoma to anti-PD-L1 immune checkpoint inhibitors with increased CD8+ T cell infiltration. ARID2 knockout in melanoma cells, in vivo anti-PD-L1 treatment, flow cytometry (CD8+ T cell infiltration), gene expression analysis The Journal of investigative dermatology Medium 33333124
2020 Loss of Arid2 in HSCs impairs lymphoid lineage differentiation in a cell-autonomous manner; Arid2 knockout enriches myeloid-biased MPP signatures while depleting lymphoid-biased MPPs, and upregulates inflammatory pathways including TLR receptors and downstream signaling genes. Conditional Arid2 knockout mouse, bone marrow transplantation, RNA-seq, in vitro lymphocyte growth assays with LPS stimulation Experimental hematology Medium 33346030
2021 ARID2 deficiency promotes lung adenocarcinoma progression; through ChIP-seq and RNA-seq integration, Hspa1a was identified as upregulated by Arid2 loss, and HSPA1A knockdown specifically inhibits malignant progression of Arid2-deficient but not Arid2-wild-type lung cancers in cell lines and animal models. Kras-based genetically engineered mouse models, ARID2 KO, ChIP-seq, RNA-seq, HSPA1A knockdown, HSPA1A inhibitor treatment, in vivo tumor models National science review High 34858604
2022 ARID2 mitigates hepatic steatosis by repressing JAK2-STAT5-PPARγ signaling; ARID2 promotes ubiquitination and degradation of JAK2 via NEDD4L (an E3 ligase for JAK2). Mechanistically, ARID2 recruits CARM1 to increase H3R17me2a at the NEDD4L promoter, activating NEDD4L transcription. Liver-specific Arid2 KO mouse (including HFD model), ChIP assay (CARM1 and H3R17me2a at NEDD4L promoter), ubiquitination assays, JAK2 inhibitor (Fedratinib) rescue, co-immunoprecipitation Cell death and differentiation High 36396719
2022 BRD4 inhibition (JQ1) induces synthetic lethality in ARID2-deficient HCC cells by exacerbating DNA double-strand breaks; both ARID2 and BRD4 synergistically maintain transcriptional enhancer-promoter loops for BRCA1, RAD51, and 53BP1, and loss of both impairs their expression, preventing DSB repair. High-throughput drug screening, JQ1 treatment in ARID2-depleted HCC cells, DNA damage assays (DSB measurement), HR and NHEJ repair pathway assays, chromatin conformation capture, gene expression assays for BRCA1/RAD51/53BP1 Oncogene Medium 35017665
2022 USP2 (ubiquitin-specific protease 2) physically interacts with ARID2 and reduces ARID2 protein degradation via the ubiquitination pathway; USP2 inhibits lung cancer cell invasion and migration by stabilizing ARID2 protein. IP-Mass Spectrometry, co-immunoprecipitation, immunofluorescent colocalization, CHX chase assay, ubiquitination assay, transwell/wound healing migration assay BioMed research international Medium 36567903
2016 ARID2 represses CD44 promoter activity and protein expression in hepatocellular carcinoma cells; overexpression of ARID2 inhibits cell invasion and metastasis in vitro and tumor growth in vivo in nude mice, mediated at least in part through transcriptional repression of CD44. Luciferase reporter assay (CD44 promoter), Western blot, adenoviral ARID2 overexpression, cell migration assay, subcutaneous tumor xenograft in nude mice Zhonghua gan zang bing za zhi Medium 27095763
2017 HBx (HBV X protein) suppresses ARID2 transcription through ATOH1-binding elements in the ARID2 promoter region (nt-1040/nt-601); ectopic ATOH1 expression or mutation of ATOH1 binding sites partially abolishes HBx-triggered ARID2 repression, and ARID2 abrogates HBx-enhanced HCC cell migration and proliferation. Promoter deletion/luciferase assays, site-directed mutagenesis of ATOH1 binding sites, ectopic ATOH1 expression, Western blot, cell migration assays Cancer science Medium 28498550
2020 ARID2 haploinsufficiency is associated with enhanced RAS-MAPK (ERK1/2) activity; this is mediated through reduced IFITM1 expression, which normally interacts with caveolin-1 (CAV-1) to inhibit ERK activation. ARID2 KO in HeLa cells increases ERK1 and ERK2 phosphorylation; patient iPSCs show impaired neuronal differentiation with enhanced RAS-MAPK activity. Transient ARID2 knockout via shRNA (ERK phosphorylation), patient-derived iPSC differentiation assays, Arid2 haploinsufficient mice (CRISPR/Cas9), IFITM1/CAV-1 expression analysis Journal of medical genetics Medium 33051312
2018 NMR backbone resonance assignment of the ARID domain of human BAF200 (ARID2) was completed, providing secondary structure information; the ARID domain has the potential to bind DNA sequences with high affinity, though the exact DNA binding specificities within the PBAF context were not yet established. NMR spectroscopy (backbone 1H, 13C, 15N chemical shift assignment) Biomolecular NMR assignments Low 30535613
2024 PBAF (defined by ARID2) occupies repressive chromatin regions co-bound by PRC2, and ARID2 loss disrupts PBAF complex formation, impairing REST transcription factor binding to its target loci. This leads to upregulation of synaptic/neuronal transcripts normally silenced by REST, a gene signature conserved in melanoma patients with ARID2 mutations. Comprehensive epigenomic profiling (ChIP-seq for SWI/SNF complexes), ARID2 knockout in melanoma cells and melanocytes, time-resolved chromatin accessibility assays, REST occupancy assays bioRxivpreprint Medium
2024 ARID2 knockout in TFE3-rearranged renal cell carcinoma (TFE3-RCC) enhances ERBB3 expression; ChIP assay demonstrated that PRCC-TFE3 directly binds and upregulates ERBB3, and ARID2 KO further enhances this effect. ARID2-KO TFE3-RCC cells show increased MAPK and ERBB3 signaling activation and heightened sensitivity to ERBB3 inhibitor AZD8931. In vitro and in vivo ARID2 KO experiments, transcriptomic analysis, ChIP assay (PRCC-TFE3 binding to ERBB3), ERBB3 inhibitor sensitivity assays, migration/proliferation assays Current issues in molecular biology Medium 39727945
2025 Arid2 is required for normal B cell differentiation in vivo; Mb1-Cre-mediated deletion causes marked reduction of splenic and circulating Follicular B cells through impaired differentiation (not proliferation or survival). Arid2 loss disrupts stage-specific gene expression programs in pro-B, pre-B, and Follicular B cells, with cumulative downregulation of B cell receptor signaling pathways, and functionally impairs germinal center expansion and IgG antibody production. Conditional KO mice (Mb1-Cre, CD19-Cre), flow cytometry, RNA-seq of isolated B cell populations, immunization assays, bone marrow transplantation bioRxivpreprint Medium 41256460

Source papers

Stage 0 corpus · 62 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2011 Inactivating mutations of the chromatin remodeling gene ARID2 in hepatocellular carcinoma. Nature genetics 338 21822264
2005 PBAF chromatin-remodeling complex requires a novel specificity subunit, BAF200, to regulate expression of selective interferon-responsive genes. Genes & development 191 15985610
2015 Long Noncoding RNA Arid2-IR Is a Novel Therapeutic Target for Renal Inflammation. Molecular therapy : the journal of the American Society of Gene Therapy 117 25743111
2014 Exome sequencing reveals frequent inactivating mutations in ARID1A, ARID1B, ARID2 and ARID4A in microsatellite unstable colorectal cancer. International journal of cancer 101 24382590
2020 Chromatin remodeling factor ARID2 suppresses hepatocellular carcinoma metastasis via DNMT1-Snail axis. Proceedings of the National Academy of Sciences of the United States of America 89 32071245
2020 ARID2 is a pomalidomide-dependent CRL4CRBN substrate in multiple myeloma cells. Nature chemical biology 75 32958952
2019 MiR-155-5p promotes oral cancer progression by targeting chromatin remodeling gene ARID2. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 72 31918270
2012 Recurrent inactivating mutations of ARID2 in non-small cell lung carcinoma. International journal of cancer 65 23047306
2021 ARID1A, ARID1B, and ARID2 Mutations Serve as Potential Biomarkers for Immune Checkpoint Blockade in Patients With Non-Small Cell Lung Cancer. Frontiers in immunology 58 34512623
2017 ARID2 modulates DNA damage response in human hepatocellular carcinoma cells. Journal of hepatology 55 28238438
2017 Heterozygosity for ARID2 loss-of-function mutations in individuals with a Coffin-Siris syndrome-like phenotype. Human genetics 54 28124119
2015 Mutations in ARID2 are associated with intellectual disabilities. Neurogenetics 53 26238514
2016 MicroRNA-155 promotes tumor growth of human hepatocellular carcinoma by targeting ARID2. International journal of oncology 50 27035278
2011 ARID2: a new tumor suppressor gene in hepatocellular carcinoma. Oncotarget 47 22095441
2016 Chromatin remodeling gene ARID2 targets cyclin D1 and cyclin E1 to suppress hepatoma cell progression. Oncotarget 36 27351279
2021 ARID2 deficiency promotes tumor progression and is associated with higher sensitivity to chemotherapy in lung cancer. Oncogene 33 33742126
2020 ARID2 Deficiency Correlates with the Response to Immune Checkpoint Blockade in Melanoma. The Journal of investigative dermatology 31 33333124
2018 The chromatin remodeling subunit Baf200 promotes normal hematopoiesis and inhibits leukemogenesis. Journal of hematology & oncology 31 29482581
2014 BAF200 is required for heart morphogenesis and coronary artery development. PloS one 31 25299188
2017 The chromatin-remodeling subunit Baf200 promotes homology-directed DNA repair and regulates distinct chromatin-remodeling complexes. The Journal of biological chemistry 30 28381560
2015 Loss of ARID1A, ARID1B, and ARID2 Expression During Progression of Gastric Cancer. Anticancer research 29 26637902
2015 miR-208-3p promotes hepatocellular carcinoma cell proliferation and invasion through regulating ARID2 expression. Experimental cell research 28 26169693
2020 Exome sequencing identifies ARID2 as a novel tumor suppressor in early-onset sporadic rectal cancer. Oncogene 27 33262464
2018 Early growth response protein-1 upregulates long noncoding RNA Arid2-IR to promote extracellular matrix production in diabetic kidney disease. American journal of physiology. Cell physiology 25 30462533
2021 Targeting HSPA1A in ARID2-deficient lung adenocarcinoma. National science review 21 34858604
2020 ARID2 Chromatin Remodeler in Hepatocellular Carcinoma. Cells 20 32977645
2020 Arid2-IR promotes NF-κB-mediated renal inflammation by targeting NLRC5 transcription. Cellular and molecular life sciences : CMLS 18 33090288
2019 Human Hepatitis B Virus Core Protein Inhibits IFNα-Induced IFITM1 Expression by Interacting with BAF200. Viruses 18 31075894
2017 HBx protein-mediated ATOH1 downregulation suppresses ARID2 expression and promotes hepatocellular carcinoma. Cancer science 18 28498550
2022 BRD4 inhibition induces synthetic lethality in ARID2-deficient hepatocellular carcinoma by increasing DNA damage. Oncogene 17 35017665
2020 Arid2 regulates hematopoietic stem cell differentiation in normal hematopoiesis. Experimental hematology 17 33346030
2022 ARID2 mitigates hepatic steatosis via promoting the ubiquitination of JAK2. Cell death and differentiation 16 36396719
2017 Confirmation of an ARID2 defect in SWI/SNF-related intellectual disability. American journal of medical genetics. Part A 16 28884947
2017 microRNA‑96 regulates the proliferation of nucleus pulposus cells by targeting ARID2/AKT signaling. Molecular medicine reports 16 28944851
2021 CREB1 acts via the miR‑922/ARID2 axis to enhance malignant behavior of liver cancer cells. Oncology reports 14 33786634
2019 Patient with anomalous skin pigmentation expands the phenotype of ARID2 loss-of-function disorder, a SWI/SNF-related intellectual disability. American journal of medical genetics. Part A 13 30838730
2018 Extending the clinical and genetic spectrum of ARID2 related intellectual disability. A case series of 7 patients. European journal of medical genetics 13 29698805
2022 USP2 Inhibits Lung Cancer Pathogenesis by Reducing ARID2 Protein Degradation via Ubiquitination. BioMed research international 12 36567903
2022 Concomitant novel ALK-SSH2, EML4-ALK and ARID2-ALK, EML4-ALK double-fusion variants and confer sensitivity to crizotinib in two lung adenocarcinoma patients, respectively. Diagnostic pathology 11 35144623
2022 SIS3 Alleviates Cisplatin-Induced Acute Kidney Injury by Regulating the LncRNA Arid2-IR-Transferrin Receptor Pathway. Kidney & blood pressure research 9 36315994
2020 Association between ARID2 and RAS-MAPK pathway in intellectual disability and short stature. Journal of medical genetics 9 33051312
2024 ARID2 mutations may relay a distinct subset of cutaneous melanoma patients with different outcomes. Scientific reports 8 38341515
2022 ARID2, a Rare Cause of Coffin-Siris Syndrome: A Clinical Description of Two Cases. Frontiers in pediatrics 8 35813374
2023 ARID2, a rare cause of Coffin-Siris syndrome: A novel microdeletion at 12q12q13.11 causing severe short stature and literature review. American journal of medical genetics. Part A 7 36756859
2020 Long non-coding RNA Arid2-IR affects advanced glycation end products-induced human retinal endothelial cell injury by binding to Smad3. International ophthalmology 7 31912402
2024 ARID2, a milder cause of Coffin-Siris Syndrome? Broadening the phenotype with 17 additional individuals. American journal of medical genetics. Part A 6 38243407
2023 miR-29a-5p regulates the malignant biological process of liver cancer cells through ARID2 regulation of EMT. Advances in clinical and experimental medicine : official organ Wroclaw Medical University 5 36530029
2015 Clinicopathological and Targeted Exome Gene Features of a Patient with Metastatic Acinic Cell Carcinoma of the Parotid Gland Harboring an ARID2 Nonsense Mutation and CDKN2A/B Deletion. Case reports in oncological medicine 5 26634163
2025 ARID2-related disorder: further delineation of the clinical phenotype of 27 novel individuals and description of an epigenetic signature. European journal of human genetics : EJHG 4 40044822
2022 Arid2-IR downregulates miR-132-3p through methylation to promote LPS-induced ALI in pneumonia. Inhalation toxicology 4 36074605
2017 Analysis of ARID2 Gene Mutation in Oral Squamous Cell Carcinoma. Asian Pacific journal of cancer prevention : APJCP 4 29072391
2023 Early progression and transformation of a splenic diffuse red pulp small B-cell lymphoma with NOTCH1, ARID2, CREBBP, and TNFRSF14 gene mutations. Leukemia research reports 3 37664441
2024 ARID2 Deficiency Enhances Tumor Progression via ERBB3 Signaling in TFE3-Rearranged Renal Cell Carcinoma. Current issues in molecular biology 2 39727945
2018 Sequential backbone resonance assignment of AT-rich interaction domain of human BAF200. Biomolecular NMR assignments 2 30535613
2016 [The regulation of CD44 expression by new tumor suppressor gene Arid2 and the influence of Arid2 on the invasion and metastasis in hepatocellular carcinoma cells]. Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology 1 27095763
2026 Targeting the STK39/ARID2 Axis to Inhibit NF-κB Signaling: A Novel Pathway for Mesenchymal Stem Cell Osteogenic Differentiation in Osteoporosis Management. Journal of musculoskeletal & neuronal interactions 0 41764760
2026 A novel variant in ARID2 causes Coffin-Siris syndrome 6 with liver cirrhosis. Gene 0 41765118
2026 [Retracted] MicroRNA‑155 promotes tumor growth of human hepatocellular carcinoma by targeting ARID2. International journal of oncology 0 42028735
2026 A guide to selecting high-performing antibodies for ARID2 (UniProt ID: Q68CP9) for use in western blot, immunoprecipitation, and immunofluorescence. F1000Research 0 42232299
2025 Arid2 promotes Follicular B-cell differentiation and antibody responses in vivo. bioRxiv : the preprint server for biology 0 41256460
2024 Revealing the clinical impact of MTOR and ARID2 gene mutations on MALT lymphoma of the alimentary canal using targeted sequencing. Diagnostic pathology 0 39054516
2021 Frameshift Variant in ARID2 in a Chilean Individual with Coffin-Siris Syndrome Phenotype. Journal of pediatric genetics 0 38721575

Missed literature

Know a paper Affinage missed for ARID2? Flag it for the maintainers and the community.

No submissions yet.